HDAC Inhibitors Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "HDAC Inhibitors Pipeline Insight 2024" report provides comprehensive insights about 50+ HDAC Inhibitors companies and 50+ pipeline drugs in HDAC Inhibitors pipeline landscape. It covers the HDAC Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. HDAC Inhibitors pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the HDAC Inhibitors Pipeline Report
• DelveInsight's HDAC Inhibitors pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for HDAC Inhibitors treatment.
• The leading HDAC Inhibitors Companies working in the market include Roche, Takeda San Diego, Italfarmaco, Sulfidris, MethylGene, EpiGen Pharmaceuticals, DAC Research, Karus Therapeutics, Xynomic Pharmaceuticals, Medivir, Mirati Therapeutics, Janssen Pharmaceuticals, and others.
• Promising HDAC Inhibitors Therapies in the various stages of development include 4SC-202, Dexamethasone, Panobinostat, and others.
• May 2024:- IrsiCaixa- An Open Label Phase I Trial to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals (BCN02-Romi).

Request a sample and discover the recent advances in HDAC Inhibitors @ HDAC Inhibitors Pipeline Outlook Report- https://www.delveinsight.com/sample-request/hdac-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HDAC Inhibitors Overview
The histone deacetylase inhibitors (HDACi) are a group of small molecules that target histone deacetylases (HDACs) by inhibiting their activity. HDACi have a long history of use in neurology and psychiatry as antiepileptics and mood stabilizers. More recently, they have been investigated as possible treatments for cancer. Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells. Eighteen human HDAC enzymes have been identified and classified into four groups based on their homology with yeast HDACs.

HDAC Inhibitors Emerging Drugs Profile
• Givinostat: Italfarmaco
Givinostat is an investigational drug discovered through Italfarmaco's internal research and development efforts in collaboration with Lorenzo Puri (SanfordBurnhamPrebys Medical Research Institute, San Diego, formerly Santa Lucia Foundation, Rome) and his team, and partnerships with Telethon and Parent Project aps. It is being evaluated for safety and efficacy for the treatment of Duchenne- and Becker- Muscular Dystrophy.

Learn more about HDAC Inhibitors in clinical trials @ HDAC Inhibitors Drugs- https://www.delveinsight.com/sample-request/hdac-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HDAC Inhibitors Therapeutics Assessment
There are approx. 50+ key companies which are developing the Histone deacetylase (HDAC) Inhibitors. The companies which have their Histone deacetylase (HDAC) Inhibitors drug candidates in the most advanced stage, i.e. phase II include, Italfarmaco.

DelveInsight's report covers around 50+ HDAC Inhibitors products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Discover more about HDAC Inhibitors in development @ HDAC Inhibitors Clinical Trials- https://www.delveinsight.com/sample-request/hdac-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HDAC Inhibitors Companies
Roche, Takeda San Diego, Italfarmaco, Sulfidris, MethylGene, EpiGen Pharmaceuticals, DAC Research, Karus Therapeutics, Xynomic Pharmaceuticals, Medivir, Mirati Therapeutics, Janssen Pharmaceuticals, and others.

HDAC Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

HDAC Inhibitors Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

To know more about HDAC Inhibitors, visit @ HDAC Inhibitors Segmentation- https://www.delveinsight.com/sample-request/hdac-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the HDAC Inhibitors Pipeline Report
• Coverage- Global
• HDAC Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HDAC Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• HDAC Inhibitors Companies- Roche, Takeda San Diego, Italfarmaco, Sulfidris, MethylGene, EpiGen Pharmaceuticals, DAC Research, Karus Therapeutics, Xynomic Pharmaceuticals, Medivir, Mirati Therapeutics, Janssen Pharmaceuticals, and others.
• HDAC Inhibitors Therapies- 4SC-202, Dexamethasone, Panobinostat, and others.

For further information on the HDAC Inhibitors Pipeline Therapeutics, reach out @ HDAC Inhibitors Products Development- https://www.delveinsight.com/sample-request/hdac-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Histone deacetylase (HDAC) Inhibitors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Histone deacetylase (HDAC) Inhibitors - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Histone deacetylase (HDAC) Inhibitors Collaboration Deals
9. Mid Stage Products (Phase II)
10. Givinostat: Italfarmaco
11. Early Stage Products (Phase I)
12. Drug Name: Company Name
13. Pre-clinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Histone deacetylase (HDAC) Inhibitors Key Companies
17. Histone deacetylase (HDAC) Inhibitors Key Products
18. Histone deacetylase (HDAC) Inhibitors- Unmet Needs
19. Histone deacetylase (HDAC) Inhibitors- Market Drivers and Barriers
20. Histone deacetylase (HDAC) Inhibitors- Future Perspectives and Conclusion
21. Histone deacetylase (HDAC) Inhibitors Analyst Views
22. Histone deacetylase (HDAC) Inhibitors Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.